Millions of US adults suffering from heartburn associated with non-erosive-gastroesophageal-reflux-disease (GERD) could benefit from an impending treatment by Phathom Pharmaceuticals.
A drug to treat a rare cancer that grows where the esophagus and stomach join has been accepted for review by the China National Medical Products Administration (NMPA).
Zosano completes site qualification batches for its subcutaneous investigational migraine treatment and readies itself for NDA submission by the end of year.